We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+12.88%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.32B
AUM Growth
+$622M
Cap. Flow
+$387M
Cap. Flow %
11.66%
Top 10 Hldgs %
45.52%
Holding
112
New
12
Increased
30
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$58.2M
2
DKS icon
Dick's Sporting Goods
DKS
+$48.3M
3
GEHC icon
GE HealthCare
GEHC
+$37.1M
4
DHR icon
Danaher
DHR
+$31.2M
5
GE icon
GE Aerospace
GE
+$24M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$95.9M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$92.5M
3
MSFT icon
Microsoft
MSFT
+$35.3M
4
CMG icon
Chipotle Mexican Grill
CMG
+$27.1M
5
UAL icon
United Airlines
UAL
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 48.97%
2 Technology 9.89%
3 Consumer Discretionary 5.64%
4 Financials 4.91%
5 Communication Services 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HD icon
26
Home Depot
HD
$352B
$47.9M 1.44%
130,721
+33,150
+34% +$12M
KURA icon
27
Kura Oncology
KURA
$817M
$46.8M 1.41%
8,116,000
+676,741
+9% +$4.15M
BAC icon
28
Bank of America
BAC
$442B
$43.9M 1.32%
927,190
+173,277
+23% +$7.29M
COF icon
29
Capital One
COF
$136B
$41.3M 1.25%
194,160
-51,062
-21% -$9.53M
FERG icon
30
Ferguson
FERG
$49.5B
$41.3M 1.25%
189,660
+59,736
+46% +$11M
GEHC icon
31
GE HealthCare
GEHC
$31.7B
$39.4M 1.19%
+532,280
New +$37.1M
BSX icon
32
Boston Scientific
BSX
$69.2B
$38M 1.14%
353,561
+91,462
+35% +$9.25M
FULC icon
33
Fulcrum Therapeutics
FULC
$288M
$35M 1.05%
5,082,900
+15,506
+0.3% +$82.9K
DHR icon
34
Danaher
DHR
$140B
$34.5M 1.04%
174,700
+161,100
+1,185% +$31.2M
RCUS icon
35
Arcus Biosciences
RCUS
$3.48B
$30M 0.91%
3,688,858
+1,127,954
+44% +$9.63M
TSLA icon
36
Tesla
TSLA
$1.27T
$29.3M 0.88%
92,357
-29,659
-24% -$8.94M
AURA icon
37
Aura Biosciences
AURA
$743M
$27.4M 0.83%
4,372,884
+1,640,998
+60% +$9.6M
INSM icon
38
Insmed
INSM
$21.5B
$24M 0.72%
238,783
-1,253,600
-84% -$95.9M
DDOG icon
39
Datadog
DDOG
$101B
$24M 0.72%
178,832
-4,399
-2% -$487K
MLYS icon
40
Mineralys Therapeutics
MLYS
$2.37B
$23.6M 0.71%
1,744,492
+76,733
+5% +$1.11M
UNH icon
41
UnitedHealth
UNH
$375B
$21.2M 0.64%
68,000
+38,100
+127% +$14.6M
JNJ icon
42
Johnson & Johnson
JNJ
$621B
$20.3M 0.61%
132,786
+23,400
+21% +$3.6M
BIIB icon
43
Biogen
BIIB
$30.5B
$19.1M 0.58%
151,890
+31,154
+26% +$3.88M
CMPX icon
44
Compass Therapeutics
CMPX
$340M
$18.6M 0.56%
+7,149,493
New +$14.7M
ERAS icon
45
Erasca
ERAS
$6.46B
$18.4M 0.56%
14,502,004
+2,187,000
+18% +$2.93M
MRK icon
46
Merck
MRK
$317B
$17.4M 0.52%
219,178
+75,078
+52% +$5.97M
GS icon
47
Goldman Sachs
GS
$313B
$17.1M 0.51%
24,108
-1,430
-6% -$829K
PVLA
48
Palvella Therapeutics
PVLA
$2.22B
$16.1M 0.49%
714,463
– –
PINS icon
49
Pinterest
PINS
$13.1B
$15.4M 0.46%
+430,025
New +$13.1M
ABEO icon
50
Abeona Therapeutics
ABEO
$388M
$15.2M 0.46%
2,676,000
-1,009,503
-27% -$5.75M
1
2
3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return

Suvretta Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Suvretta Capital Management held 112 positions worth $3.32B, up 23% from $2.69B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Suvretta Capital Management deployed $387M of net new capital in Q2 2025, opening 12 new positions and adding to 30 existing holdings. Its largest new stake was Dick's Sporting Goods: 260,465 shares worth $51.5M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $95.9M trimmed.

  • Suvretta Capital Management's largest Q2 2025 buy was Dick's Sporting Goods: 260,465 shares worth $51.5M.
  • Suvretta Capital Management added most to Coca-Cola in Q2 2025, an estimated $58.2M increase.
  • Suvretta Capital Management's biggest Q2 2025 reduction was Insmed, cutting an estimated $95.9M.
  • Suvretta Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $92.5M.
  • Suvretta Capital Management's ten largest holdings make up 46% of its $3.32B portfolio in Q2 2025.
  • Suvretta Capital Management opened 12 new positions and closed 14 in Q2 2025.
  • Suvretta Capital Management's portfolio value rose 23% quarter-over-quarter to $3.32B.

Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.